Moreover, in a case series of 8 NMO patients (6 AQP4-positive) with highly active disease activity despite treatment with rituximab, administration of tocilizumab, a humanized anti-IL-6 receptor antibody, resulted in relapse control in all patients [138]. This evidence concerns the gene AQP4 and neuromyelitis optica.